Q9992 HCPCS Level II code: Injection, buprenorphine extended-release (sublocade), greater than 100 mg
Q9992 is the HCPCS code for “Injection, buprenorphine extended-release (sublocade), greater than 100 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
Short description: Buprenorphine xr over 100 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q9992 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jul 1, 2018
Where Q9992 sits
- 1Q codesTemporary codes
- 2Active code Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q9992 mean?
Q9992 is the HCPCS code for “Injection, buprenorphine extended-release (sublocade), greater than 100 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q9992?
CMS lists Q9992’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9992
All Q codesQ9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgQ9986Injection, hydroxyprogesterone caproate, (makena), 10 mgQ9987Pathogen(s) test for plateletsQ9988Platelets, pheresis, pathogen-reduced, each unitQ9989Ustekinumab, for intravenous injection, 1 mgQ9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mgQ9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgQ9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachQ9995Injection, emicizumab-kxwh, 0.5 mgQ9996Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mgQ9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mgQ9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg